OTCD
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD (NCT06488313) | Arcturus Therapeutics, Inc. | 2024-11-04 |
| Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810 (NCT05526066) | Arcturus Therapeutics, Inc. | 2022-10-17 |
Track OTCD automatically
Every clearance here is in the API, with alerts when new ones post.